Opendata, web and dolomites

PREDICT SIGNED

Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREDICT project word cloud

Explore the words cloud of the PREDICT project. It provides you a very rough idea of what is the project "PREDICT" about.

biomarkers    slows    accurately    metrics    tms    predicts    medicine       treat    costly    truly    savings    body    people    dramatically    equivalent    disorder    weight    prevents    ranges    personalised    brain    equal    remission    treatment    accounting    52    responsiveness    life    time    improves    determines    brains    diagnose    electroencephalogram    prescribed    mdd    psa    mental    quantifying    functions    day    normal    population    measured    countless    individual    invasive    organ    trial    tool    patients    total    percentage    ownership    reduces    healthcare    symptoms    right    modern    cholesterol    eluded    compare    rarely    98    fat    predict    event    measuring    substantiation    rates    treatments    depressive    33    delays    receiving    patient    doctors    temperature    million    hinders    suffer    therapies    diagnosis    health    heavy    quality    elminda    gdp    validated    unable    suspected    error    antidepressants    easily    amelioration    ailments    disorders      

Project "PREDICT" data sheet

The following table provides information about the project.

Coordinator
ELMINDA LTD 

Organization address
address: Shenkar 1, WeWork Building
city: HERZLIYA
postcode: 4673314
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙798˙450 €
 EC max contribution 1˙958˙915 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELMINDA LTD IL (HERZLIYA) coordinator 1˙958˙915.00

Map

 Project objective

Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More